Treatment Dosage and Mode of Administration Sample Clauses

Treatment Dosage and Mode of Administration. ‌ The injection technique (skin disinfection material, type of syringe, type and gauge of the intradermal needle, penetration angle, depth) will be the technique customarily used by the Investigator. The type of gauge of the injection needle will be recorded in the CRFs. PLLA: two treatment sessions at 4-week interval with the first treatment at Visit 1 and the second treatment at Visit 3. Each treatment session will be consisted of multiple deep dermal injections, up to 9 mL/session (or up to 4.5 mL/NLF/session), into the left and right NLFs of each subject according to the IFU. The treatment amount for each PLLA subject will be determined at the Investigator discretion to achieve an optimal correction. Within each PLLA subject, the amount of each treatment needs to be equal at the left and right NLFs because of the identical WAS scores. The treatment volume injected during each treatment session for each subject will be recorded in the CRFs. CaHA: up to two treatment sessions at 4-week interval with the required first treatment at Visit 1 and an optional second treatment at Visit 3 to achieve an optimal cosmetic correction. Each treatment session will be consisted of multiple subdermal injections, up to 1.5 mL/session (or up to 0.75 mL/NLF/session), into the left and right NLFs of each subject according to the IFU. The second treatment is optional and will be determined based on the Investigator assessment. If the subject needs a second treatment, an appropriate amount will be determined at the Investigator discretion to achieve an optimal outcome. The amount of each treatment needs to be equal at the left and right NLFs because of the identical WAS scores. The treatment volume injected during each treatment session for each subject will be recorded in the CRFs.
Sample 1
AutoNDA by SimpleDocs

Related to Treatment Dosage and Mode of Administration

  • Procurement of Goods and Services (a) If the HSP is subject to the procurement provisions of the BPSAA, the HSP will abide by all directives and guidelines issued by the Management Board of Cabinet that are applicable to the HSP pursuant to the BPSAA.

  • Administration of Medication Employees required to administer or apply medication(s) prescribed by a qualified medical practitioner, will be trained at the Employer's expense. Employees who have not received this training will not be permitted to administer such substances.

  • Allocation and use of scarce resources Any procedures for the allocation and use of scarce resources, including frequencies, numbers and rights of way, will be carried out in an objective, timely, transparent and non-discriminatory manner. The current state of allocated frequency bands will be made publicly available, but detailed identification of frequencies allocated for specific government uses is not required.

  • USE OF U.S. FOREST SERVICE INSIGNIA In order for the Cooperators to use the U.S. Forest Service insignia on any published media, such as a Web page, printed publication, or audiovisual production, permission must be granted from the U.S. Forest Service’s Office of Communications. A written request must be submitted and approval granted in writing by the Office of Communications (Washington Office) prior to use of the insignia.

  • Application of Funding Techniques to Programs 6.3.1 The State shall apply the following funding techniques when requesting Federal funds for the component cash flows of the programs listed in sections 4.2 and 4.3 of this Agreement.

  • Required Procurement Procedures for Obtaining Goods and Services The Grantee shall provide maximum open competition when procuring goods and services related to the grant-assisted project in accordance with Section 287.057, Florida Statutes.

  • Orally Administered Anticancer Medication In accordance with RIGL § 27-20-67, prescription drug coverage for orally administered anticancer medications is provided at a level no less favorable than coverage for intravenously administered or injected cancer medications covered under your medical benefit.

  • TRANSITIONAL AND FINAL PROVISIONS Article 23

  • LIMITATIONS OF COVERED MEDICAL SERVICES In order to be covered, the Member’s Attending Physician must specifically prescribe such services and such services must be consequent to treatment of the cleft lip or cleft palate.

  • National Treatment and Most-favoured-nation Provisions (1) Neither Contracting Party shall in its territory subject investments or returns of nationals or companies of the other Contracting Party to treatment less favourable than that which it accords to investments or returns of its own nationals or companies or to investments or returns of nationals or companies of any third State.

Time is Money Join Law Insider Premium to draft better contracts faster.